Pharmafile.com’s weekly COVID-19 news round-up
pharmafile | November 18, 2020 | News story | Research and Development |
The coronavirus news this week focuses on the Pfizer-BioNTech vaccine, with clinical trial participants receiving the vaccine saying it created side effects that felt similar to a “severe hangover”, while it has been reported that Pfizer CEO Albert Bourla sold 62% of his stock in the company on the same day the vaccine’s clinical trial results were revealed.
1. First interim Phase 3 data shows promise for Russia’s Sputnik V COVID-19 vaccine – Published on 11/11/20
The first interim Phase 3 data for Russia’s Sputnik V COVID-19 vaccine have been released by the Gamaleya Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF).
2. Pfizer/BioNTech vaccine side effects feel like a “severe hangover” – Published on 12/11/20
Clinical trial participants receiving the Pfizer/BioNTech coronavirus vaccine have said it created side effects that felt similar to a “severe hangover.”
3. Pfizer CEO cashes in shares for $5.6m following strong Phase 3 COVID-19 vaccine data – Published on 12/11/20
With the news that Pfizer and BioNTech’s COVID-19 vaccine candidate demonstrated 90% efficacy in a Phase 3 interim analysis, it has been reported that Pfizer CEO Albert Bourla sold 62% of his stock in the company on the same day the results were unveiled.
4. Hotels, gyms and restaurants carry highest COVID-19 spread risk, new study says – Published on 11/11/20
Reopening hotels, gyms and restaurants carries the highest risk of spreading coronavirus, according to a new study.
5. Pfizer launches pilot delivery programme for its coronavirus vaccine – Published on 17/11/20
Pfizer is set to launch its first delivery programme for the COVID-19 vaccine it developed with BioNTech. It will be located in multiple sites across America; the company said it has selected New Mexico, Tennessee, Rhode Island and Texas for the programme because of their differences in size and immunisation infrastructure.
Conor Kavanagh
